全文获取类型
收费全文 | 547篇 |
免费 | 30篇 |
国内免费 | 19篇 |
出版年
2024年 | 1篇 |
2023年 | 14篇 |
2022年 | 19篇 |
2021年 | 31篇 |
2020年 | 22篇 |
2019年 | 27篇 |
2018年 | 28篇 |
2017年 | 18篇 |
2016年 | 11篇 |
2015年 | 24篇 |
2014年 | 38篇 |
2013年 | 68篇 |
2012年 | 34篇 |
2011年 | 21篇 |
2010年 | 11篇 |
2009年 | 19篇 |
2008年 | 13篇 |
2007年 | 10篇 |
2006年 | 9篇 |
2005年 | 15篇 |
2004年 | 18篇 |
2003年 | 9篇 |
2002年 | 9篇 |
2001年 | 5篇 |
2000年 | 9篇 |
1999年 | 11篇 |
1998年 | 5篇 |
1997年 | 8篇 |
1996年 | 5篇 |
1995年 | 11篇 |
1994年 | 8篇 |
1993年 | 5篇 |
1992年 | 9篇 |
1991年 | 6篇 |
1990年 | 10篇 |
1989年 | 9篇 |
1988年 | 6篇 |
1987年 | 9篇 |
1986年 | 7篇 |
1985年 | 2篇 |
1984年 | 1篇 |
1982年 | 1篇 |
排序方式: 共有596条查询结果,搜索用时 15 毫秒
61.
Jun Yang Manlong Qi Xiang Fei Xia Wang Kefeng Wang 《International journal of biological sciences》2021,17(12):3188
Long non-coding RNAs (lncRNAs) are a series of non-coding RNAs that lack open reading frameworks. Accumulating evidence suggests important roles for lncRNAs in various diseases, including cancers. Recently, lncRNA H19 (H19) became a research focus due to its ectopic expression in human malignant tumors, where it functioned as an oncogene. Subsequently, H19 was confirmed to be involved in tumorigenesis and malignant progression in many tumors and had been implicated in promoting cell growth, invasion, migration, epithelial-mesenchymal transition, metastasis, and apoptosis. H19 also sequesters some microRNAs, facilitating a multilayer molecular regulatory mechanism. In this review, we summarize the abnormal overexpression of H19 in human cancers, which suggests wide prospects for further research into the diagnosis and treatment of cancers. 相似文献
62.
Prevalent mutations in prostate cancer 总被引:3,自引:0,他引:3
Dong JT 《Journal of cellular biochemistry》2006,97(3):433-447
Quantitative and structural genetic alterations cause the development and progression of prostate cancer. A number of genes have been implicated in prostate cancer by genetic alterations and functional consequences of the genetic alterations. These include the ELAC2 (HPC2), MSR1, and RNASEL (HPC1) genes that have germline mutations in familial prostate cancer; AR, ATBF1, EPHB2 (ERK), KLF6, mitochondria DNA, p53, PTEN, and RAS that have somatic mutations in sporadic prostate cancer; AR, BRCA1, BRCA2, CHEK2 (RAD53), CYP17, CYP1B1, CYP3A4, GSTM1, GSTP1, GSTT1, PON1, SRD5A2, and VDR that have germline genetic variants associated with either hereditary and/or sporadic prostate cancer; and ANXA7 (ANX7), KLF5, NKX3-1 (NKX3.1), CDKN1B (p27), and MYC that have genomic copy number changes affecting gene function. More genes relevant to prostate cancer remain to be identified in each of these gene groups. For the genes that have been identified, most need additional genetic, functional, and/or biochemical examination. Identification and characterization of these genes will be a key step for improving the detection and treatment of prostate cancer. 相似文献
63.
64.
Oncogene-induced telomere dysfunction enforces cellular senescence in human cancer precursor lesions 总被引:1,自引:0,他引:1
Suram A Kaplunov J Patel PL Ruan H Cerutti A Boccardi V Fumagalli M Di Micco R Mirani N Gurung RL Hande MP d'Adda di Fagagna F Herbig U 《The EMBO journal》2012,31(13):2839-2851
In normal human somatic cells, telomere dysfunction causes cellular senescence, a stable proliferative arrest with tumour suppressing properties. Whether telomere dysfunction-induced senescence (TDIS) suppresses cancer growth in humans, however, is unknown. Here, we demonstrate that multiple and distinct human cancer precursor lesions, but not corresponding malignant cancers, are comprised of cells that display hallmarks of TDIS. Furthermore, we demonstrate that oncogenic signalling, frequently associated with initiating cancer growth in humans, dramatically affected telomere structure and function by causing telomeric replication stress, rapid and stochastic telomere attrition, and consequently telomere dysfunction in cells that lack hTERT activity. DNA replication stress induced by drugs also resulted in telomere dysfunction and cellular senescence in normal human cells, demonstrating that telomeric repeats indeed are hypersensitive to DNA replication stress. Our data reveal that TDIS, accelerated by oncogene-induced DNA replication stress, is a biological response of cells in human cancer precursor lesions and provide strong evidence that TDIS is a critical tumour suppressing mechanism in humans. 相似文献
65.
66.
Glenn S. Van Aller Nicolas Reynoird Olena Barbash Michael Huddleston Shichong Liu Anne-Flore Zmoos Patrick McDevitt Robert Sinnamon BaoChau Le Gloria Mas Roland Annan Julien Sage Benjamin A. Garcia Peter J. Tummino Or Gozani Ryan G. Kruger 《Epigenetics》2012,7(4):340-343
Smyd3 is a lysine methyltransferase implicated in chromatin and cancer regulation. Here we show that Smyd3 catalyzes histone H4 methylation at lysine 5 (H4K5me). This novel histone methylation mark is detected in diverse cell types and its formation is attenuated by depletion of Smyd3 protein. Further, Smyd3-driven cancer cell phenotypes require its enzymatic activity. Thus, Smyd3, via H4K5 methylation, provides a potential new link between chromatin dynamics and neoplastic disease. 相似文献
67.
目的:采用高分辨率熔解曲线分析法检测结直肠癌中KRAS基因突变,探讨其用于临床检测的可行性。方法:首先用高分辨率熔解曲线分析法检测64例结直肠癌患者KRAS基因第2外显子的突变情况,再用直接测序法对结果进行验证。结果:通过高分辨率熔解曲线分析法检测,发现有23例KRAS基因突变(35.9%),经直接测序法验证,证实所有患者的突变情况与高分辨率熔解曲线法的结果完全一致;共检测出6种KRAS突变类型,G12D(GGT>GAT)的突变率最高(47.8%),G12D、G12V和G13D等3种常见突变型占总突变数的78.3%。结论:与直接测序法相比,应用高分辨率熔解曲线分析法检测KRAS基因突变具有操作简单快捷、结果准确、成本低的优点,适合应用于临床检测。 相似文献
68.
发展了一种可用于快速检测K-ras癌基因点突变的电化学发光PCR(ECL-PCR)分析方法,该法采用三联吡啶钌标记的上游引物和生物素标记的下游引物对目的片段进行PCR扩增;随后,采用限制性内切酶MvaI对扩增产物进行酶切,由于突变导致酶切位点的丢失,所以只有野生型样品能被切断;通过生物素与链霉亲和素包被的磁珠连接,将生物素标记的DNA片段收集到反应池中进行电化学发光检测。采用该法对20例结肠癌组织中的K-ras癌基因第12位密码子进行点突变分析,得出其中有9例存在点突变,点突变率为45%。该方法操作简便、安全、快速、灵敏,可用于快速检测K-ras癌基因点突变。 相似文献
69.
癌症发生机理的研究进展 总被引:3,自引:0,他引:3
根据近年的研究进展,从癌基因与抑癌基因的突变及环境因素的影响等方面综述了癌症的发生机理。 相似文献
70.
应用双色FISH技术检测肝癌中HER—2的定量扩增及其临床意义 总被引:1,自引:0,他引:1
为探讨原发性肝细胞癌(HCC)中原癌基因HER-2的扩增激活情况及其与临床病理特征和预后的关系,应用双色荧光原位杂交(dualFISH)技术检测42例原发性肝癌间期细胞核中HER-2的扩增和17号染色体的数目及其比值,并用统计学分析HER-2的扩增与临床病理特征及预后的相关性.结果在42例肝癌中有9例HER-2扩增(amplification),占21.4%,其中高拷贝扩增(HC)有4例(9.5%),低拷贝扩增(LC)有5例(11.9%),HER-2的扩增与性别、年龄、AFP水平、HBV感染、术后复发及临床分期无关(P>0.05),而与术后2年生存期相关(P=0.046)且HER-2扩增病人的肿瘤有比无扩增病人的肿瘤增大的倾向(P=0.085);同时,在42例肝癌中有3l例为HER-2拷贝数增加(gain),占73.8%,其中9例(21.4%)为扩增所致,22例(52.4%)为17号染色体多倍体或异倍体(polysomy17/aneusomy17)所致,HER-2拷贝数增加与性别、临床分期、肿瘤大小、术后复发及术后2年生存期无关(P>0.05),但与年龄、AFP水平和HBV感染有关(P<0.05).以上结果提示原发性肝癌中存在较低频的HER-2癌基因扩增激活及较高频的17号染色体异倍体/多倍体;HER-2癌基因的扩增激活可能与部分肝癌的发生发展有关,是肝癌术后生存期短的有价值独立预后因子. 相似文献